Helicobacter Pylori Infection : Diagnostic Strategies in Primary Diagnosis and After Therapy
Accurate diagnosis of Helicobacter pylori infection pre- and post-treatment is mandatory in the current era of decreasing prevalence and increasing antibiotic resistance. The diagnostic performance of most tests is poorer in clinical situations with low bacterial density which is seen in conditions such as atrophic gastritis or intake of antisecretory and antibiotic medications. Noninvasive tests require less cost and resource but provide excellent accuracy; however, endoscopy with testing of gastric biopsy specimens is indicated where alarming symptoms are present or antibiotic susceptibility testing by culture is desired. Newer modalities such as polymerase chain reaction testing provide additional virulence and antibiotic sensitivity profiling. This article outlines new developments and the key parameters of each test, as careful selection of test modality within the clinical context is required for adequate management of infected symptomatic patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 61(2016), 1 vom: 21. Jan., Seite 19-24 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atkinson, Nathan S S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.05.2016 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10620-015-3877-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM252954513 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM252954513 | ||
| 003 | DE-627 | ||
| 005 | 20231224165214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-015-3877-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0843.xml |
| 035 | |a (DE-627)NLM252954513 | ||
| 035 | |a (NLM)26391269 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atkinson, Nathan S S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Helicobacter Pylori Infection |b Diagnostic Strategies in Primary Diagnosis and After Therapy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2016 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Accurate diagnosis of Helicobacter pylori infection pre- and post-treatment is mandatory in the current era of decreasing prevalence and increasing antibiotic resistance. The diagnostic performance of most tests is poorer in clinical situations with low bacterial density which is seen in conditions such as atrophic gastritis or intake of antisecretory and antibiotic medications. Noninvasive tests require less cost and resource but provide excellent accuracy; however, endoscopy with testing of gastric biopsy specimens is indicated where alarming symptoms are present or antibiotic susceptibility testing by culture is desired. Newer modalities such as polymerase chain reaction testing provide additional virulence and antibiotic sensitivity profiling. This article outlines new developments and the key parameters of each test, as careful selection of test modality within the clinical context is required for adequate management of infected symptomatic patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Endoscopy | |
| 650 | 4 | |a Eradication | |
| 650 | 4 | |a Helicobacter pylori infection | |
| 650 | 4 | |a Histology | |
| 650 | 4 | |a Polymerase chain reaction | |
| 650 | 4 | |a Rapid urease test | |
| 650 | 4 | |a Serology | |
| 650 | 4 | |a Stool antigen test | |
| 650 | 4 | |a Urea breath test | |
| 650 | 7 | |a Antibodies, Bacterial |2 NLM | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Urease |2 NLM | |
| 650 | 7 | |a EC 3.5.1.5 |2 NLM | |
| 700 | 1 | |a Braden, Barbara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 61(2016), 1 vom: 21. Jan., Seite 19-24 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2016 |g number:1 |g day:21 |g month:01 |g pages:19-24 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-015-3877-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2016 |e 1 |b 21 |c 01 |h 19-24 | ||